All articles
Maintaining Your Results With GLP-1s
Maintaining Your Results With GLP-1s
Dr. Zoë Lees (PhD)
Dr. Sophie Dix (BSc, PhD)
21 April 2026 | Updated: 7 May 2026
7 May 2026


Reaching your goal weight is a real achievement, and you deserve to feel proud of yourself.
But it can also feel surprisingly nerve-wracking. Many people tell us that the closer they get to their target, the more anxious they feel about what comes next.
What happens to the medication? Will I regain the weight? What if I need to start all over again?
These are normal questions, and you’re not alone in asking them. This guide is here to answer them honestly, lay out your options clearly and remind you that our support doesn’t stop just because you’ve reached a certain number on the scale.
Article Summary:
- Stopping or pausing GLP-1 treatment is a completely valid choice. There’s no pressure to stay on medication forever, and returning later is straightforward and judgment-free.
- Weight fluctuations are normal and don’t mean something has gone wrong. Maintenance is a range rather than a fixed number.
- Medication is one part of managing obesity, but the lifestyle changes you’ve made matter and work alongside it.
Understanding obesity
Obesity is recognised by the World Health Organisation as a chronic, relapsing medical condition. [1] That framing matters because it changes how we think about treatment.
Think about high blood pressure medication. When someone stops taking it, their blood pressure doesn’t stay low. It usually starts to rise again.
GLP-1 medications work similarly. They help regulate appetite, quieten food noise and improve blood sugar control. But when you stop taking them, your body’s baseline hunger signals come back. [2]
This is why, for many people, ongoing treatment becomes part of a long-term management plan. Just as it is with blood pressure. So, the decision to stop or continue medication deserves careful thought, rather than an automatic stop when you hit a goal.
What happens when you reach your goal weight?
Reaching your goal weight marks the beginning of your maintenance phase. With MedExpress, your treatment won’t be stopped automatically. What happens next is your choice. There’s no single “right” answer, and there’s no pressure to make any particular decision.
It’s worth knowing that small changes on the scales are normal. Hydration, hormones and what you ate yesterday can all move the number on the scale by a kilogram or more. A small increase doesn’t mean something has gone wrong, and it doesn’t automatically mean your medication dose needs to change.
Think of maintenance as a range, rather than a single number on the scales.
Your maintenance options
Stay on your current dose
If your current dose is working well and you’re tolerating it, you can continue on it. Many people choose this option to maintain their weight loss results and support long-term health goals.
Taper to a lower dose
Some people prefer a lighter maintenance approach. A lower dose can still provide meaningful appetite support and weight stability, often with fewer side effects and at a lower cost. You can explore this at your own pace.
Take a treatment break or stop altogether
If you decide to pause or stop, that’s completely fine. There’s no pressure to stay on medication, and no embarrassment in returning if and when you want to.
Whatever option you choose, it doesn’t have to be permanent. Our door is always open.
About the BMI threshold
We currently prescribe GLP-1 treatments down to a BMI of 21. If your BMI drops below this, we will need to pause treatment.
You don’t need to aim for a BMI below 25 to be in maintenance. If you feel healthy and well at a BMI of 26 or 27, that’s a completely valid place to maintain. Your goals are your own.
For reference:
| BMI | Weight Status |
|---|---|
| Below 18.5 | Underweight |
| 18.5-24.9 | Healthy weight |
| 25-29.9 | Overweight |
| 30 or above | Obesity |
BMI categories based on NHS guidelines.
Taking a break and coming back
Many people will pause treatment at some point. It might be to see how they feel without it, because of cost, or simply because they want to try. This is a natural part of the journey. You’re always welcome back, with no judgement and no unnecessary barriers. And if you do restart, you won’t need your BMI to be 30 or above again.
Here’s how we approach restart doses:
| Time since last treatment | What to expect |
|---|---|
| Less than 8 weeks | You can usually return to your previous dose or move up as planned. |
| 8-12 weeks | Clinical review is required to determine the safest dose. You may continue at your previous dose or step down. |
| 12 weeks to 6 months | Clinical review is required. You may continue at your previous dose, step down, or restart treatment at the lowest dose. |
| More than 6 months | Restart at the lowest dose. |
Supporting yourself through the transition
Whether you decide to stay on medication or stop, the habits you’ve built are your most valuable asset.
- Prioritise protein and fibre. Both help you feel fuller for longer, which becomes especially important if your GLP-1 support is reduced or you decide to stop treatment.
- Keep moving. Strength training in particular helps you maintain muscle mass, which supports your metabolism even at rest.
- Trust yourself to notice changes. Increased food noise, feeling hungrier between meals, or gradual weight gain are signals worth paying attention to early. If you ever feel you need extra support, you can always return to treatment.
We’re here for the long term
Maintenance is an ongoing process rather than a single destination, and it can be emotionally demanding. The anxiety many people feel at this stage is real and valid. We don’t expect you to have it all figured out the moment you reach your goal weight.
Whatever path you choose, it’s your decision to make. And if you ever want to come back after stopping treatment, we’ll make that as straightforward as possible.
References
- World Health Organization. Obesity and overweight [Internet]. 2025 Dec 8 [cited 2026 Mar 20]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
- West S, Scragg J, Aveyard P, Oke JL, Willis L, Haffner SJP, Knight H, Wang D, Morrow S, Heath L, Jebb SA, Koutoukidis DA. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026 Jan 7;392:e085304.
Next scheduled review date: 7 May 2029

Foundayo vs Wegovy Pill: How the Two Oral GLP-1 Weight Loss Tablets Compare

Foundayo Side Effects: What To Expect Before You Begin Treatment

Orforglipron Vs Mounjaro For Weight Loss: What’s The Difference And Which Is Right For You?

Mounjaro Patches: Are They Real, Safe, Or Effective For Weight Loss?
Authors

Written by: Dr. Zoë Lees (PhD)
Dr. Zoë Lees is a medical writer at MedExpress specialising in obesity and health communication. She completed her PhD at the University of Glasgow, where she investigated adipose tissue (fat tissue) function in pregnancies complicated by pre-eclampsia and gestational diabetes. Her work focuses on translating complex clinical evidence into clear, engaging and evidence-based health information for patients and the public. At MedExpress, Zoë contributes to clinical content, educational resources and media communications across areas including weight management, GLP-1 therapies and metabolic disease. Zoë is particularly interested in improving public understanding of obesity as a chronic condition and ensuring patients have access to accurate, accessible health information grounded in current scientific evidence.

Medically reviewed by: Dr. Sophie Dix (BSc, PhD)
Dr. Sophie Dix is Head of Medical Affairs at MedExpress. A behavioural neuroscientist by training, Sophie has spent 30 years working at the intersection of medical research, pharmacology, technology and patient communication across the pharmaceutical industry, health technology and charity sectors. At MedExpress, Sophie's role is to ensure that everything the organisation does is grounded in the most current science. That means translating complex clinical evidence into accessible health information across the website, clinical pathways and media communications. It also means working with external press and broadcast media as a named expert commentator, making the science behind weight management and GLP-1 treatments understandable to a general audience. A core part of Sophie's work is building MedExpress's Real-World Evidence (RWE) programme: learning systematically from patient outcomes to understand what works in practice, not just in clinical trials. This patient-level insight feeds directly into improving patient experience and health outcomes. Sophie believes that patients make better decisions when they have access to accurate, evidence-based information. As an advocate for meaningful change in how obesity is understood, Sophie works to reduce stigma and raise awareness of the condition as an illness. This includes reframing the conversation around GLP-1s from aesthetics to public health, while highlighting the health benefits of weight loss and weight management.
Note from the experts
Remember: This blog shouldn’t be regarded as medical advice, diagnosis, or treatment. We make sure everything we publish is fact checked by clinical experts and regularly reviewed, but it may not always reflect the most recent health guidelines. Always speak to your doctor about any health concerns you have.